{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,7]],"date-time":"2025-12-07T09:06:42Z","timestamp":1765098402622,"version":"3.41.2"},"reference-count":144,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,10,31]],"date-time":"2023-10-31T00:00:00Z","timestamp":1698710400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>The clinical prognosis of the HER2-overexpressing (HER2-OE) subtype of breast cancer (BC) is influenced by the immune infiltrate of the tumor. Specifically, monocytic cells, which are promoters of pro-tumoral immunosuppression, and NK cells, whose basal cytotoxic function may be enhanced with therapeutic antibodies. One of the standards of care for HER2<jats:sup>+<\/jats:sup> BC patients includes the combination of the anti-HER2 antibodies trastuzumab and pertuzumab. This dual combination was a breakthrough against trastuzumab resistance; however, this regimen does not yield complete clinical benefit for a large fraction of patients. Further therapy refinement is still hampered by the lack of knowledge on the immune mechanism of action of this antibody-based dual HER2 blockade.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>To explore how the dual antibody challenge influences the phenotype and function of immune cells infiltrating the HER2-OE BC microenvironment, we developed <jats:italic>in vitro<\/jats:italic> 3D heterotypic cell models of this subtype. The models comprised aggregates of HER2<jats:sup>+<\/jats:sup> BC cell lines and human peripheral blood mononuclear cells. Cells were co-encapsulated in a chemically inert alginate hydrogel and maintained in agitation-based culture system for up to 7 days.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The 3D models of the HER2-OE immune microenvironment retained original BC molecular features; the preservation of the NK cell compartment was achieved upon optimization of culture time and cytokine supplementation. Challenging the models with the standard-of-care combination of trastuzumab and pertuzumab resulted in enhanced immune cytotoxicity compared with trastuzumab alone. Features of the response to therapy within the immune tumor microenvironment were recapitulated, including induction of an immune effector state with NK cell activation, enhanced cell apoptosis and decline of immunosuppressive PD-L1<jats:sup>+<\/jats:sup> immune cells.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>This work presents a unique human 3D model for the study of immune effects of anti-HER2 biologicals, which can be used to test novel therapy regimens and improve anti-tumor immune function.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fimmu.2023.1267621","type":"journal-article","created":{"date-parts":[[2023,10,31]],"date-time":"2023-10-31T09:35:43Z","timestamp":1698744943000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":8,"title":["Immune microenvironment dynamics of HER2 overexpressing breast cancer under dual anti-HER2 blockade"],"prefix":"10.3389","volume":"14","author":[{"given":"Sofia","family":"Batalha","sequence":"first","affiliation":[]},{"given":"Catarina Monteiro","family":"Gomes","sequence":"additional","affiliation":[]},{"given":"Catarina","family":"Brito","sequence":"additional","affiliation":[]}],"member":"1965","published-online":{"date-parts":[[2023,10,31]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)32417-5","article-title":"HER2-positive breast cancer","volume":"389","author":"Loibl","year":"2017","journal-title":"Lancet"},{"key":"B3","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1038\/s41392-019-0069-2","article-title":"Targeted therapeutic options and future perspectives for HER2-positive breast cancer","volume":"4","author":"Wang","year":"2019","journal-title":"Signal Transduct Target Ther"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.breast.2015.07.008","article-title":"Clinical implications of the intrinsic molecular subtypes of breast cancer","volume":"24","author":"Prat","year":"2015","journal-title":"Breast"},{"key":"B5","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1038\/s41572-019-0111-2","article-title":"Breast cancer","volume":"5","author":"Harbeck","year":"2019","journal-title":"Nat Rev Dis Prim"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-07-2068","article-title":"Elements related to heterogeneity of antibody-dependent cell cytotoxicity in patients under trastuzumab therapy for primary operable breast cancer overexpressing her2","volume":"67","author":"Varchetta","year":"2007","journal-title":"Cancer Res"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-04-0225","article-title":"Pilot study of the mechanism of action of preoperative trastuzumab in patients with primary operable breast tumors overexpressing HER2","volume":"10","author":"Gennari","year":"2004","journal-title":"Clin Cancer Res"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1002\/1521-4141(2001010)31:10<3016::AID-IMMU3016>3.0.CO;2-J","article-title":"Interleukin-2 enhances the natural killer cell response to Herceptin-coated Her2\/neu-positive breast cancer cells","volume":"31","author":"Carson","year":"2001","journal-title":"Eur J Immunol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1007\/s11033-019-05059-0","article-title":"In vitro cytotoxic effect of Trastuzumab in combination with Pertuzumab in breast cancer cells is improved by interleukin-2 activated NK cells","volume":"46","author":"Asgari","year":"2019","journal-title":"Mol Biol Rep"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3944","article-title":"Natural and therapy-induced immunosurveillance in breast cancer","volume":"21","author":"Kroemer","year":"2015","journal-title":"Nat Med"},{"key":"B11","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1186\/s40425-016-0165-6","article-title":"Clinical significance of tumor-infiltrating lymphocytes in breast cancer","volume":"4","author":"Stanton","year":"2016","journal-title":"J Immunother Cancer"},{"key":"B12","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1016\/j.cell.2018.05.060","article-title":"Single-cell map of diverse immune phenotypes in the breast tumor microenvironment","volume":"174","author":"Azizi","year":"2018","journal-title":"Cell"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.1016\/j.cell.2019.03.005","article-title":"A single-cell atlas of the tumor and immune ecosystem of human breast cancer","volume":"177","author":"Wagner","year":"2019","journal-title":"Cell"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01323-8","article-title":"A single-cell map of intratumoral changes during anti-PD1 treatment of patients with breast cancer","volume":"27","author":"Bassez","year":"2021","journal-title":"Nat Med"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1038\/s41588-021-00911-1","article-title":"A single-cell and spatially resolved atlas of human breast cancers","volume":"53","author":"Wu","year":"2021","journal-title":"Nat Genet"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3909","article-title":"The prognostic landscape of genes and infiltrating immune cells across human cancers","volume":"21","author":"Gentles","year":"2015","journal-title":"Nat Med"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1104303108","article-title":"Leukocyte composition of human breast cancer","volume":"109","author":"Ruffell","year":"2012","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-021-06447-6","article-title":"Immune cell profiles of metastatic HER2-positive breast cancer patients according to the sites of metastasis","volume":"191","author":"Honkanen","year":"2022","journal-title":"Breast Cancer Res Treat"},{"key":"B19","doi-asserted-by":"publisher","first-page":"e24720","DOI":"10.4161\/onci.24720","article-title":"Tumor-infiltrating lymphocytes, breast cancer subtypes and therapeutic efficacy","volume":"2","author":"Loi","year":"2013","journal-title":"Oncoimmunology"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2015.215","article-title":"Clinical relevance of host immunity in breast cancer: From TILs to the clinic","volume":"13","author":"Savas","year":"2016","journal-title":"Nat Rev Clin Oncol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13058-015-0621-0","article-title":"Human breast cancer cells educate macrophages toward the M2 activation status","volume":"17","author":"Sousa","year":"2015","journal-title":"Breast Cancer Res"},{"key":"B22","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1016\/j.ccell.2019.02.009","article-title":"Human tumor-associated macrophage and monocyte transcriptional landscapes reveal cancer-specific reprogramming, biomarkers, and therapeutic targets","volume":"35","author":"Cassetta","year":"2019","journal-title":"Cancer Cell"},{"key":"B23","doi-asserted-by":"publisher","first-page":":15025","DOI":"10.1038\/npjbcancer.2015.25","article-title":"Tumor-associated macrophages: Unwitting accomplices in breast cancer Malignancy","volume":"2","author":"Williams","year":"2016","journal-title":"NPJ Breast Cancer"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2011.261","article-title":"T-bet expression in intratumoral lymphoid structures after neoadjuvant trastuzumab plus docetaxel for HER2-overexpressing breast carcinoma predicts survival","volume":"105","author":"Ladoire","year":"2011","journal-title":"Br J Cancer"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-2365","article-title":"NK cell infiltrates and HLA class I expression in primary HER2+ breast cancer predict and uncouple pathological response and disease-free survival","volume":"25","author":"Muntasell","year":"2019","journal-title":"Clin Cancer Res"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1038\/s43018-021-00190-z","article-title":"Spatial proteomic characterization of HER2-positive breast tumors through neoadjuvant therapy predicts response","volume":"2","author":"McNamara","year":"2021","journal-title":"Nat Cancer"},{"key":"B27","doi-asserted-by":"publisher","first-page":":68","DOI":"10.1038\/s41523-022-00430-0","article-title":"Adaptive immune signature in HER2-positive breast cancer in NCCTG (Alliance) N9831 and NeoALTTO trials","volume":"8","author":"Chumsri","year":"2022","journal-title":"NPJ Breast Cancer"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.706606","article-title":"The therapeutic effectiveness of neoadjuvant trastuzumab plus chemotherapy for HER2-positive breast cancer can be predicted by tumor-infiltrating lymphocytes and PD-L1 expression","volume":"11","author":"Shang","year":"2022","journal-title":"Front Oncol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-15-2338","article-title":"Tumor-infiltrating lymphocytes: A predictive and prognostic biomarker in neoadjuvant-treated HER2-positive breast cancer","volume":"22","author":"Heppner","year":"2016","journal-title":"Clin Cancer Res"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2016.1257452","article-title":"Tumor-infiltrating lymphocyte composition, organization and PD-1\/PD-l1 expression are linked in breast cancer","volume":"6","author":"Buisseret","year":"2017","journal-title":"Oncoimmunology"},{"key":"B31","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.canlet.2018.08.025","article-title":"Tumor-associated macrophages secrete CCL2 and induce the invasive phenotype of human breast epithelial cells through upregulation of ERO1-\u03b1 and MMP-9","volume":"437","author":"Lee","year":"2018","journal-title":"Cancer Lett"},{"key":"B32","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1016\/j.cell.2018.09.007","article-title":"Immune checkpoint inhibition overcomes ADCP-induced immunosuppression by macrophages","volume":"175","author":"Su","year":"2018","journal-title":"Cell"},{"key":"B33","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/2162402X.2018.1484980","article-title":"Impact of chemotactic factors and receptors on the cancer immune infiltrate: a bioinformatics study revealing homogeneity and heterogeneity among patient cohorts","volume":"7","author":"Stoll","year":"2018","journal-title":"Oncoimmunology"},{"key":"B34","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1172\/jci.insight.131882","article-title":"CD47 blockade augmentation of trastuzumab antitumor efficacy dependent on antibody-dependent cellular phagocytosis","volume":"4","author":"Tsao","year":"2019","journal-title":"JCI Insight"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6602930","article-title":"Trastuzumab-based treatment of HER2-positive breast cancer: An antibody-dependent cellular cytotoxicity mechanism","volume":"94","author":"Arnould","year":"2006","journal-title":"Br J Cancer"},{"key":"B36","doi-asserted-by":"publisher","first-page":"5310","DOI":"10.1038\/s41467-022-32782-3","article-title":"Targeted immunotherapy against distinct cancer-associated fibroblasts overcomes treatment resistance in refractory HER2+ breast tumors","volume":"13","author":"Rivas","year":"2022","journal-title":"Nat Commun"},{"key":"B37","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1038\/s41698-021-00163-6","article-title":"Immune microenvironment characterisation and dynamics during anti-HER2-based neoadjuvant treatment in HER2-positive breast cancer","volume":"5","author":"Griguolo","year":"2021","journal-title":"NPJ Precis Oncol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13061305","article-title":"The peripheral immune landscape of breast cancer: clinical findings and in vitro models for biomarker discovery","volume":"13","author":"Batalha","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1016\/j.trecan.2020.10.009","article-title":"3D in vitro model (R)evolution: unveiling tumor\u2013stroma interactions","volume":"7","author":"Rodrigues","year":"2021","journal-title":"Trends Cancer"},{"key":"B40","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jim.2015.07.003","article-title":"Establishment of a heterotypic 3D culture system to evaluate the interaction of TREG lymphocytes and NK cells with breast cancer","volume":"426","author":"Augustine","year":"2015","journal-title":"J Immunol Methods"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-19-0342","article-title":"An engineered tumor-on-a-chip device with breast cancer\u2013immune cell interactions for assessing T-cell recruitment","volume":"80","author":"Aung","year":"2020","journal-title":"Cancer Res"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1016\/j.cclet.2018.07.013","article-title":"Co-culture of tumor spheroids and monocytes in a collagen matrix-embedded microfluidic device to study the migration of breast cancer cells","volume":"30","author":"Yuan","year":"2019","journal-title":"Chin Chem Lett"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2018.1553477","article-title":"Evaluating natural killer cell cytotoxicity against solid tumors using a microfluidic model","volume":"8","author":"Ayuso","year":"2019","journal-title":"Oncoimmunology"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6602901","article-title":"Macrophages promote angiogenesis in human breast tumour spheroids in vivo","volume":"94","author":"Bingle","year":"2006","journal-title":"Br J Cancer"},{"key":"B45","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2013\/279505","article-title":"MMP1, MMP9, and COX2 expressions in promonocytes are induced by breast cancer cells and correlate with collagen degradation, transformation-like morphological changes in MCF-10A acini, and tumor aggressiveness","volume":"2013","author":"Chimal-Ram\u00edrez","year":"2013","journal-title":"BioMed Res Int"},{"key":"B46","doi-asserted-by":"publisher","first-page":":1135","DOI":"10.1038\/s41467-019-08989-2","article-title":"Apoptotic tumor cell-derived microRNA-375 uses CD36 to alter the tumor-associated macrophage phenotype","volume":"10","author":"Frank","year":"2019","journal-title":"Nat Commun"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1016\/j.imbio.2010.05.019","article-title":"Importance of CCL2-CCR2A\/2B signaling for monocyte migration into spheroids of breast cancer-derived fibroblasts","volume":"215","author":"Ksiazkiewicz","year":"2010","journal-title":"Immunobiology"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1083\/jcb.202001134","article-title":"Cancer cells educate natural killer cells to a metastasis-promoting cell state","volume":"219","author":"Chan","year":"2020","journal-title":"J Cell Biol"},{"key":"B49","doi-asserted-by":"publisher","first-page":"3884","DOI":"10.1016\/j.celrep.2018.12.015","article-title":"Dissecting effects of anti-cancer drugs and cancer-associated fibroblasts by on-chip reconstitution of immunocompetent tumor microenvironments","volume":"25","author":"Nguyen","year":"2018","journal-title":"Cell Rep"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.3581","article-title":"MPGES-1-derived PGE2 suppresses CD80 expression on tumorassociated phagocytes to inhibit anti-tumor immune responses in breast cancer","volume":"6","author":"Olesch","year":"2015","journal-title":"Oncotarget"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1016\/j.cclet.2019.02.017","article-title":"Microfluidic three-dimensional biomimetic tumor model for studying breast cancer cell migration and invasion in the presence of interstitial flow","volume":"30","author":"Song","year":"2019","journal-title":"Chin Chem Lett"},{"key":"B52","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1158\/0008-5472.CAN-19-1310","article-title":"Phosphorylation of Rab7 by TBK1\/IKK\u03f5 regulates innate immune signaling in triple-negative breast cancer","volume":"80","author":"Ritter","year":"2020","journal-title":"Cancer Res"},{"key":"B53","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1136\/jitc-2020-000676","article-title":"Inhibition of TGF- \u03b2- Receptor signaling augments the antitumor function of ROR1-specific CAR T-cells against triple-negative breast cancer","volume":"8","author":"St\u00fcber","year":"2020","journal-title":"J Immunother Cancer"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.01593","article-title":"A bispecific antibody-based approach for targeting mesothelin in triple negative breast cancer","volume":"10","author":"Del Bano","year":"2019","journal-title":"Front Immunol"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.126345","article-title":"ROR1-CAR T cells are effective against lung and breast cancer in advanced microphysiologic 3D tumor models","volume":"4","author":"Wallstabe","year":"2019","journal-title":"JCI Insight"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1002\/smll.202004282","article-title":"Cancer-on-a-chip for modeling immune checkpoint inhibitor and tumor interactions","volume":"17","author":"Jiang","year":"2021","journal-title":"Small"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1002\/bit.26961","article-title":"Three-dimensional microfluidic tumor\u2013macrophage system for breast cancer cell invasion","volume":"116","author":"Mi","year":"2019","journal-title":"Biotechnol Bioeng"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.7150\/jca.18457","article-title":"Breast cancer cell line classification and Its relevance with breast tumor subtyping","volume":"8","author":"Dai","year":"2017","journal-title":"J Cancer"},{"key":"B59","doi-asserted-by":"crossref","DOI":"10.1007\/978-3-030-34025-4_23","article-title":"In vitro and ex vivo models \u2013 the tumor microenvironment in a flask","volume-title":"Tumor microenvironment advances in experimental medicine and biology","author":"Pinto","year":"2020"},{"key":"B60","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.biomaterials.2015.11.030","article-title":"Modelling the tumour microenvironment in long-term microencapsulated 3D co-cultures recapitulates phenotypic features of disease progression","volume":"78","author":"Estrada","year":"2016","journal-title":"Biomaterials"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1016\/j.biomaterials.2018.02.030","article-title":"3D-3-culture: A tool to unveil macrophage plasticity in the tumour microenvironment","volume":"163","author":"Rebelo","year":"2018","journal-title":"Biomaterials"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1038\/74704","article-title":"Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets","volume":"6","author":"Clynes","year":"2000","journal-title":"Nat Med"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbiotec.2016.01.031","article-title":"Adaptable stirred-tank culture strategies for large scale production of multicellular spheroid-based tumor cell models","volume":"221","author":"Santo","year":"2016","journal-title":"J Biotechnol"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.3390\/cells9010107","article-title":"Monocytes as endothelial progenitor cells (EPCs), another brick in the wall to disentangle tumor angiogenesis","volume":"9","author":"Lopes-Coelho","year":"2020","journal-title":"Cells"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-2007","article-title":"Effects of HER family\u2013targeting tyrosine kinase inhibitors on antibody-dependent cell-mediated cytotoxicity in HER2-expressing breast cancer","volume":"27","author":"Collins","year":"2021","journal-title":"Clin Cancer Res"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1007\/s10637-018-0649-y","article-title":"HER-targeted tyrosine kinase inhibitors enhance response to trastuzumab and pertuzumab in HER2-positive breast cancer","volume":"37","author":"Canonici","year":"2019","journal-title":"Invest New Drugs"},{"key":"B67","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.nbt.2021.05.003","article-title":"Development of antibodies against the notch ligand Delta-Like-1 by phage display with activity against breast cancer cells","volume":"64","author":"Sales-Dias","year":"2021","journal-title":"N Biotechnol"},{"key":"B68","doi-asserted-by":"publisher","first-page":"18571","DOI":"10.1038\/s41598-021-97894-0","article-title":"Application of LDH assay for therapeutic efficacy evaluation of ex vivo tumor models","volume":"11","author":"Cox","year":"2021","journal-title":"Sci Rep"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2006.10.008","article-title":"A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes","volume":"10","author":"Neve","year":"2006","journal-title":"Cancer Cell"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1007\/BF00666165","article-title":"Differentiation state and invasiveness of human breast cancer cell lines","volume":"31","author":"Sommers","year":"1994","journal-title":"Breast Cancer Res Treat"},{"key":"B71","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.molonc.2007.02.004","article-title":"The morphologies of breast cancer cell lines in three-dimensional assays correlate with their profiles of gene expression","volume":"1","author":"Kenny","year":"2007","journal-title":"Mol Oncol"},{"key":"B72","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1007\/s10911-016-9359-2","article-title":"Generation of multicellular breast cancer tumor spheroids: comparison of different protocols","volume":"21","author":"Froehlich","year":"2016","journal-title":"J Mammary Gland Biol Neoplasia"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.3892\/ijo.31.6.1403","article-title":"Diversity of cell-mediated adhesions in breast cancer spheroids","volume":"31","author":"Ivascu","year":"2007","journal-title":"Int J Oncol"},{"key":"B74","doi-asserted-by":"publisher","first-page":":415","DOI":"10.3390\/toxics10080415","article-title":"Morphometrical, morphological, and immunocytochemical characterization of a tool for cytotoxicity research: 3D cultures of breast cell lines grown in ultra-low attachment plates","volume":"10","author":"Malh\u00e3o","year":"2022","journal-title":"Toxics"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1038\/onc.2008.394","article-title":"Comparison of 3D and 2D tumor models reveals enhanced HER2 activation in 3D associated with an increased response to trastuzumab","volume":"28","author":"Pickl","year":"2009","journal-title":"Oncogene"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djs396","article-title":"Selective inhibition of HER2-positive breast cancer cells by the HIV protease inhibitor nelfinavir","volume":"104","author":"Shim","year":"2012","journal-title":"JNCI J Natl Cancer Inst"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-17-0696","article-title":"Defective cyclin B1 induction in trastuzumab-emtansine (T-DM1) acquired resistance in HER2-positive breast cancer","volume":"23","author":"Sabbaghi","year":"2017","journal-title":"Clin Cancer Res"},{"key":"B78","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/s10020-021-00274-7","article-title":"Diagnostic and prognostic impact of cytokeratin 18 expression in human tumors: a tissue microarray study on 11,952 tumors","volume":"27","author":"Menz","year":"2021","journal-title":"Mol Med"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-03-0114","article-title":"Down-regulated expression of cytokeratin 18 promotes progression of human breast cancer","volume":"10","author":"Woelfle","year":"2004","journal-title":"Clin Cancer Res"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.3892\/or.2019.7069","article-title":"Downregulation of cytokeratin 18 enhances BCRP-mediated multidrug resistance through induction of epithelial-mesenchymal transition and predicts poor prognosis in breast cancer","volume":"41","author":"Shi","year":"2019","journal-title":"Oncol Rep"},{"key":"B81","article-title":"Mechanisms of inactivation of E-cadherin in breast cancer cell lines","volume":"58","author":"Hiraguri","year":"1998","journal-title":"Cancer Res"},{"key":"B82","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pone.0077281","article-title":"Mammosphere formation in breast carcinoma cell lines depends upon expression of E-cadherin","volume":"8","author":"Manuel Iglesias","year":"2013","journal-title":"PloS One"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2021.749364","article-title":"ZO-1 intracellular localization organizes immune response in non-small cell lung cancer","volume":"9","author":"Neyrinck-Leglantier","year":"2021","journal-title":"Front Cell Dev Biol"},{"key":"B84","doi-asserted-by":"publisher","first-page":"1","DOI":"10.26508\/lsa.202201398","article-title":"Intensive single-cell analysis reveals immune-cell diversity among healthy individuals","volume":"5","author":"Kashima","year":"2022","journal-title":"Life Sci Alliance"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2017.01544","article-title":"Interplay between Natural killer cells and Anti-HER2 antibodies: Perspectives for breast cancer immunotherapy","volume":"8","author":"Muntasell","year":"2017","journal-title":"Front Immunol"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1172\/JCI90387","article-title":"CD56bright NK cells exhibit potent antitumor responses following IL-15 priming","volume":"127","author":"Wagner","year":"2017","journal-title":"J Clin Invest"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-04-425397","article-title":"NK cell CD16 surface expression and function is regulated by a disintegrin and metalloprotease-17 (ADAM17)","volume":"121","author":"Romee","year":"2013","journal-title":"Blood"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.711621","article-title":"Activation of ADAM17 by IL-15 limits human NK cell proliferation","volume":"12","author":"Mishra","year":"2021","journal-title":"Front Immunol"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1608069113","article-title":"Precision glycocalyx editing as a strategy for cancer immunotherapy","volume":"113","author":"Xiao","year":"2016","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1038\/s41589-020-0622-x","article-title":"Targeted glycan degradation potentiates the anticancer immune response in vivo","volume":"16","author":"Gray","year":"2020","journal-title":"Nat Chem Biol"},{"key":"B91","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.canlet.2018.05.009","article-title":"Trastuzumab upregulates PD-L1 as a potential mechanism of trastuzumab resistance through engagement of immune effector cells and stimulation of IFN\u03b3 secretion","volume":"430","author":"Chaganty","year":"2018","journal-title":"Cancer Lett"},{"key":"B92","article-title":"Targeting breast cancer stem cells with HER2-specific antibodies and natural killer cells","volume":"3","author":"Diessner","year":"2013","journal-title":"Am J Cancer Res"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2016.1204503","article-title":"The combination of trastuzumab and pertuzumab administered at approved doses may delay development of trastuzumab resistance by additively enhancing antibody-dependent cell-mediated cytotoxicity","volume":"8","author":"T\u00f3th","year":"2016","journal-title":"MAbs"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-09-738211","article-title":"Anti-CD20-interleukin-21 fusokine targets Malignant B cells via direct apoptosis and NK-cell\u2013dependent cytotoxicity","volume":"129","author":"Bhatt","year":"2017","journal-title":"Blood"},{"key":"B95","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/2162402X.2018.1512942","article-title":"HER2 signaling regulates the tumor immune microenvironment and trastuzumab efficacy","volume":"8","author":"Triulzi","year":"2019","journal-title":"Oncoimmunology"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1111\/his.12607","article-title":"High numbers of macrophages, especially M2-like (CD163-positive), correlate with hyaluronan accumulation and poor outcome in breast cancer","volume":"66","author":"Tiainen","year":"2015","journal-title":"Histopathology"},{"key":"B97","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.cytogfr.2019.06.003","article-title":"CD14: Biology and role in the pathogenesis of disease","volume":"48","author":"Wu","year":"2019","journal-title":"Cytokine Growth Factor Rev"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.643771","article-title":"Macrophage biology and mechanisms of immune suppression in breast cancer","volume":"12","author":"Mehta","year":"2021","journal-title":"Front Immunol"},{"key":"B99","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.canlet.2021.01.025","article-title":"Non-matrigel scaffolds for organoid cultures","volume":"504","author":"Kaur","year":"2021","journal-title":"Cancer Lett"},{"key":"B100","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s42003-021-02417-2","article-title":"3D tumor spheroid microarray for high-throughput, high-content natural killer cell-mediated cytotoxicity","volume":"4","author":"Gopal","year":"2021","journal-title":"Commun Biol"},{"key":"B101","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1016\/j.isci.2019.07.034","article-title":"Paracrine crosstalk between fibroblasts and ER+ Breast cancer cells creates an IL1\u03b2-enriched niche that promotes tumor growth","volume":"19","author":"Chatterjee","year":"2019","journal-title":"iScience"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.1016\/j.bios.2022.114616","article-title":"Visualization of natural killer cell-mediated killing of cancer cells at single-cell resolution in live zebrafish","volume":"216","author":"Yang","year":"2022","journal-title":"Biosens Bioelectron"},{"key":"B103","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3791\/50665","article-title":"Production of large numbers of size-controlled tumor spheroids using microwell plates","author":"Razian","year":"2013","journal-title":"J Vis Exp"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.1186\/1479-5876-6-25","article-title":"Correlation between NK function and response to trastuzumab in metastatic breast cancer patients","volume":"6","author":"Beano","year":"2008","journal-title":"J Transl Med"},{"key":"B105","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1186\/s12967-015-0680-0","article-title":"Analysis of in vitro ADCC and clinical response to trastuzumab: possible relevance of Fc\u03b3RIIIA\/Fc\u03b3RIIA gene polymorphisms and HER-2 expression levels on breast cancer cell lines","volume":"13","author":"Boero","year":"2015","journal-title":"J Transl Med"},{"key":"B106","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/srep46347","article-title":"Glycoengineering of pertuzumab and its impact on the pharmacokinetic\/pharmacodynamic properties","volume":"7","author":"Luo","year":"2017","journal-title":"Sci Rep"},{"key":"B107","doi-asserted-by":"publisher","first-page":":1677","DOI":"10.3390\/ijms18081677","article-title":"Regulation of NKG2D-dependent NK Cell functions: The Yin and the Yang of receptor endocytosis","volume":"18","author":"Molfetta","year":"2017","journal-title":"Int J Mol Sci"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-11-0792","article-title":"Human breast tumor cells induce self-tolerance mechanisms to avoid NKG2D-mediated and DNAM-mediated NK cell recognition","volume":"71","author":"Mamessier","year":"2011","journal-title":"Cancer Res"},{"key":"B109","doi-asserted-by":"publisher","first-page":":e102341","DOI":"10.1371\/journal.pone.0102341","article-title":"Plasma membrane proteomics of human breast cancer cell lines identifies potential targets for breast cancer diagnosis and treatment","volume":"9","author":"Ziegler","year":"2014","journal-title":"PloS One"},{"key":"B110","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1006\/excr.2001.5210","article-title":"A heterologous 3-D coculture model of breast tumor cells and fibroblasts to study tumor-associated fibroblast differentiation","volume":"266","author":"Kunz-Schughart","year":"2001","journal-title":"Exp Cell Res"},{"key":"B111","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/2162402X.2016.1267891","article-title":"Overcoming resistance to HER2-targeted therapy with a novel HER2\/CD3 bispecific antibody","volume":"6","author":"Lopez-Albaitero","year":"2017","journal-title":"Oncoimmunology"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.4161\/mabs.29865","article-title":"The level of HER2 expression is a predictor of antibody-HER2 trafficking behavior in cancer cells","volume":"6","author":"Ram","year":"2014","journal-title":"MAbs"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-017-4453-8","article-title":"HER2 intratumoral heterogeneity is independently associated with incomplete response to anti-HER2 neoadjuvant chemotherapy in HER2-positive breast carcinoma","volume":"166","author":"Hou","year":"2017","journal-title":"Breast Cancer Res Treat"},{"key":"B114","doi-asserted-by":"publisher","first-page":":e954893","DOI":"10.4161\/21624011.2014.954893","article-title":"A catalog of HLA type, HLA expression, and neoepitope candidates in human cancer cell lines","volume":"3","author":"Boegel","year":"2014","journal-title":"Oncoimmunology"},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-11-0072","article-title":"B7-H3 silencing increases paclitaxel sensitivity by abrogating Jak2\/Stat3 phosphorylation","volume":"10","author":"Liu","year":"2011","journal-title":"Mol Cancer Ther"},{"key":"B116","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-15-1538","article-title":"Immunoregulatory protein B7-H3 reprograms glucose metabolism in cancer cells by ROS-mediated stabilization of HIF1a","volume":"76","author":"Lim","year":"2016","journal-title":"Cancer Res"},{"key":"B117","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0805458105","article-title":"The contrasting role of B7-H3","volume":"105","author":"Hofmeyer","year":"2008","journal-title":"Proc Natl Acad Sci"},{"key":"B118","doi-asserted-by":"publisher","DOI":"10.1038\/cr.2017.90","article-title":"Inhibition of the B7-H3 immune checkpoint limits tumor growth by enhancing cytotoxic lymphocyte function","volume":"27","author":"Lee","year":"2017","journal-title":"Cell Res"},{"key":"B119","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/2162402X.2015.1100790","article-title":"Trastuzumab upregulates expression of HLA-ABC and T cell costimulatory molecules through engagement of natural killer cells and stimulation of IFN\u03b3 secretion","volume":"5","author":"Chaganty","year":"2016","journal-title":"Oncoimmunology"},{"key":"B120","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1126\/sciadv.aax3160","article-title":"B7-H3\u00d74-1BB bispecific antibody augments antitumor immunity by enhancing terminally differentiated CD8+ tumor-infiltrating lymphocytes","volume":"7","author":"You","year":"2021","journal-title":"Sci Adv"},{"key":"B121","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/srep43006","article-title":"Cellular glycosylation affects Herceptin binding and sensitivity of breast cancer cells to doxorubicin and growth factors","volume":"7","author":"Peiris","year":"2017","journal-title":"Sci Rep"},{"key":"B122","doi-asserted-by":"publisher","first-page":"2997","DOI":"10.3892\/or.2018.6680","article-title":"Increasing HER2 a2,6 sialylation facilitates gastric cancer progression and resistance via the akt and ERK pathways","volume":"40","author":"Liu","year":"2018","journal-title":"Oncol Rep"},{"key":"B123","doi-asserted-by":"publisher","first-page":":e1362530","DOI":"10.1080\/2162402X.2017.1362530","article-title":"Resistance to HER2-targeted anti-cancer drugs is associated with immune evasion in cancer cells and their derived extracellular vesicles","volume":"6","author":"Martinez","year":"2017","journal-title":"Oncoimmunology"},{"key":"B124","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdr484","article-title":"Trastuzumab induces antibody-dependent cell-mediated cytotoxicity (ADCC) in HER-2-non-amplified breast cancer cell lines","volume":"23","author":"Collins","year":"2012","journal-title":"Ann Oncol"},{"key":"B125","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-018-0409-3","article-title":"Genetic and transcriptional evolution alters cancer cell line drug response","volume":"560","author":"Ben-David","year":"2018","journal-title":"Nature"},{"key":"B126","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdp304","article-title":"Association between gain-of-function mutations in PIK3CA and resistance to HER2-targeted agents in HER2 -amplified breast cancer cell lines","volume":"21","author":"Kataoka","year":"2010","journal-title":"Ann Oncol"},{"key":"B127","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-09-1171","article-title":"Activated phosphoinositide 3-kinase\/AKT signaling confers resistance to trastuzumab but not lapatinib","volume":"9","author":"O\u2019Brien","year":"2010","journal-title":"Mol Cancer Ther"},{"key":"B128","doi-asserted-by":"publisher","first-page":":2612\u201335","DOI":"10.1200\/JCO.22.00519","article-title":"Systemic therapy for advanced human epidermal growth factor receptor 2-positive breast cancer: ASCO guideline update","volume":"36","author":"Giordano","year":"2022","journal-title":"J Clin Oncol"},{"key":"B129","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.03399","article-title":"Neoadjuvant chemotherapy, endocrine therapy, and targeted therapy for breast cancer: ASCO guideline","volume":"39","author":"Korde","year":"2021","journal-title":"J Clin Oncol"},{"key":"B130","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-08-4597","article-title":"Strongly enhanced antitumor activity of trastuzumab and pertuzumab combination treatment on HER2-positive human xenograft tumor models","volume":"69","author":"Scheuer","year":"2009","journal-title":"Cancer Res"},{"key":"B131","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13143540","article-title":"Trastuzumab mechanism of action; 20 years of research to unravel a dilemma","volume":"13","author":"Maadi","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B132","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1007\/s10549-019-05371-0","article-title":"Prognostic and clinicopathological value of PD \u2212 L1 expression in primary breast cancer : a meta \u2212 analysis","volume":"178","author":"Huang","year":"2019","journal-title":"Breast Cancer Res Treat"},{"key":"B133","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyab063","article-title":"Combining analysis of tumor-infiltrating lymphocytes (TIL) and PD-L1 refined the prognostication of breast cancer subtypes","volume":"27","author":"Ni","year":"2022","journal-title":"Oncologist"},{"key":"B134","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-022-11578-x","article-title":"Immunological profiles of the breast cancer microenvironment represented by tumor-infiltrating lymphocytes and PD-L1 expression","volume":"12","author":"Hanamura","year":"2022","journal-title":"Sci Rep"},{"key":"B135","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1186\/s13578-022-00823-5","article-title":"Targeting tumor-associated macrophages for cancer treatment","volume":"12","author":"Li","year":"2022","journal-title":"Cell Biosci"},{"key":"B136","doi-asserted-by":"publisher","DOI":"10.1002\/eji.201344130","article-title":"TLR activation of tumor-associated macrophages from ovarian cancer patients triggers cytolytic activity of NK cells","volume":"44","author":"Bellora","year":"2014","journal-title":"Eur J Immunol"},{"key":"B137","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-022-03365-4","article-title":"Exploring the potential of combining IL-2-activated NK cells with an anti-PDL1 monoclonal antibody to target multiple myeloma-associated macrophages","volume":"72","author":"Ehlers","year":"2023","journal-title":"Cancer Immunol Immunother"},{"key":"B138","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-005-0058-x","article-title":"Humanization of a recombinant monoclonal antibody to produce a therapeutic HER dimerization inhibitor, pertuzumab","volume":"55","author":"Adams","year":"2006","journal-title":"Cancer Immunol Immunother"},{"key":"B139","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0216095","article-title":"Cryo-EM structure of HER2-trastuzumab-pertuzumab complex","volume":"14","author":"Hao","year":"2019","journal-title":"PloS One"},{"key":"B140","doi-asserted-by":"publisher","first-page":":342","DOI":"10.3390\/cancers10100342","article-title":"Mechanisms underlying the action and synergism of trastuzumab and pertuzumab in targeting HER2-positive breast cancer","volume":"10","author":"Nami","year":"2018","journal-title":"Cancers (Basel)"},{"key":"B141","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1186\/s13046-020-01653-4","article-title":"A novel culture method that sustains ER\u03b1 signaling in human breast cancer tissue microstructures","volume":"39","author":"Cartaxo","year":"2020","journal-title":"J Exp Clin Cancer Res"},{"key":"B142","doi-asserted-by":"publisher","first-page":"R123","DOI":"10.1186\/bcr3069","article-title":"Anti-tumor activity and toxicokinetics analysis of MGAH22, an anti-HER2 monoclonal antibody with enhanced Fc\u03b3 receptor binding properties","volume":"13","author":"Nordstrom","year":"2011","journal-title":"Breast Cancer Res"},{"key":"B143","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1001\/jamaoncol.2020.7932","article-title":"Efficacy of margetuximab vs trastuzumab in patients with pretreated ERBB2-positive advanced breast cancer","volume":"7","author":"Rugo","year":"2021","journal-title":"JAMA Oncol"},{"key":"B144","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22094774","article-title":"Trastuzumab deruxtecan: changing the destiny of HER2 expressing solid tumors","volume":"22","author":"Indini","year":"2021","journal-title":"Int J Mol Sci"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1267621\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,31]],"date-time":"2023-10-31T09:35:52Z","timestamp":1698744952000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1267621\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,31]]},"references-count":144,"alternative-id":["10.3389\/fimmu.2023.1267621"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2023.1267621","relation":{},"ISSN":["1664-3224"],"issn-type":[{"type":"electronic","value":"1664-3224"}],"subject":[],"published":{"date-parts":[[2023,10,31]]},"article-number":"1267621"}}